Evidence map›Paper›PMID 33922652›Full record

ArticleCancers2021

Multiregional Sequencing of IDH-WT Glioblastoma Reveals High Genetic Heterogeneity and a Dynamic Evolutionary History.

Sara Franceschi, Prospero Civita, Francesco Pasqualetti, Francesca Lessi, Martina Modena, Serena Barachini, Mariangela Morelli, Orazio Santonocito, Riccardo Vannozzi, Geoffrey J Pilkington and 4 more

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sara FranceschiFondazione Pisana per la Scienza, 56017 Pisa, Italy.ORCID 0000-0002-4246-4407
Prospero CivitaSchool of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF10 3NB, UK.ORCID 0000-0002-8313-1094
Francesco PasqualettiDepartment of Radiation Oncology, Azienda Ospedaliera Universitaria Pisana, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-0788-1205
Francesca LessiFondazione Pisana per la Scienza, 56017 Pisa, Italy.
Martina ModenaFondazione Pisana per la Scienza, 56017 Pisa, Italy.
Serena BarachiniFondazione Pisana per la Scienza, 56017 Pisa, Italy.
Mariangela MorelliFondazione Pisana per la Scienza, 56017 Pisa, Italy.
Orazio SantonocitoDivision of Neurosurgery, Spedali Riuniti di Livorno-USL Toscana Nord-Ovest, 57124 Livorno, Italy.
Riccardo VannozziDepartment of Neurosurgery, University of Pisa, 56126 Pisa, Italy.
Geoffrey J PilkingtonSchool of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF10 3NB, UK.
Valerio OrtenziDepartment of Translational Research and New Technologies in Medicine and Surgery, Division of Surgical Pathology, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-2570-0295
Antonio Giuseppe NaccaratoDepartment of Translational Research and New Technologies in Medicine and Surgery, Division of Surgical Pathology, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-8195-9445
Paolo AretiniFondazione Pisana per la Scienza, 56017 Pisa, Italy.ORCID 0000-0003-1075-4319
Chiara Maria MazzantiFondazione Pisana per la Scienza, 56017 Pisa, Italy.ORCID 0000-0002-7249-9221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is one of the most common and lethal primary neoplasms of the brain. Patient survival has not improved significantly over the past three decades and the patient median survival is just over one year. Tumor heterogeneity is thought to be a major determinant of therapeutic failure and a major reason for poor overall survival. This work aims to comprehensively define intra- and inter-tumor heterogeneity by mapping the genomic and mutational landscape of multiple areas of three primary IDH wild-type (IDH-WT) glioblastomas. Using whole exome sequencing, we explored how copy number variation, chromosomal and single loci amplifications/deletions, and mutational burden are spatially distributed across nine different tumor regions. The results show that all tumors exhibit a different signature despite the same diagnosis. Above all, a high inter-tumor heterogeneity emerges. The evolutionary dynamics of all identified mutations within each region underline the questionable value of a single biopsy and thus the therapeutic approach for the patient. Multiregional collection and subsequent sequencing are essential to try to address the clinical challenge of precision medicine. Especially in glioblastoma, this approach could provide powerful support to pathologists and oncologists in evaluating the diagnosis and defining the best treatment option.

Indexed as

clonal evolutionglioblastomamultiregional sequencingspatial heterogeneitytemporal heterogeneitytumor phylogenytumor progression

Identifiers

PMID33922652
PMCPMC8122908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.